Therapy with tocilizumab, a monoclonal antibody against the IL-6 receptor, showed improvement in fatigue symptomatology among patients with rheumatoid arthritis, a disorder strongly related to depression, which positions IL-6 as a therapeutic target of depression [60, 61]. Here, IL6 is linked to rheumatoid arthritis.